BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Primovist / Eovist in Renally Impaired Patients
Phase 4
Completed
- Conditions
- Contrast Media
- Interventions
- Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 357
- Registration Number
- NCT00908596
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15729
- Registration Number
- NCT00909051
Bonefos and the Consumption of Analgesics
Completed
- Conditions
- Bone Neoplasms
- Interventions
- Drug: Bonefos (Clodronate, BAY94-8393)
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 149
- Registration Number
- NCT00909142
Androcur Effects on Quality of Life
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 245
- Registration Number
- NCT00908674
LEVITRA® 20mg Special Drug Use Investigation (Long-term)
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Vardenafil, (Levitra, BAY38-9456)
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1221
- Registration Number
- NCT00909233
Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT00905879
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
Completed
- Conditions
- Contraception
- Interventions
- Drug: EE30/DRSP (Yasmin, BAY86-5131)Drug: Any other OC
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5446
- Registration Number
- NCT00905684
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Completed
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2015-07-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 702
- Registration Number
- NCT00902135
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Phase 3
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 732
- Registration Number
- NCT00901901
Transdermal Contraceptive Patch - Endometrial Effects Study
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: Ethinylestradiol/Gestogene (BAY86-5016)
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 92
- Registration Number
- NCT00896571